A Phase 4 interventional study of high-dose rosuvastatin and low-dose rosuvastatin plus ezetimibe in Acute Coronary Syndrome and Carotid Atherosclerotic Plaque With Inflammation, sponsored by Yuhan Corporation. Completed at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-08-16.
Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing rosuvastatin in Acute Coronary Syndrome — 2 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Acute Coronary Syndrome.
Among the 16 studies testing rosuvastatin in Acute Coronary Syndrome, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 13th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 16 studies testing rosuvastatin in Acute Coronary Syndrome are open now, in 1 country. Recruiting first, the newest first:
King Edward Medical University · Sites in Pakistan
Ages 18–65
Assiut University
Ages 18+
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
This study's enrollment of 50 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 193 across the 16 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Yuhan Corporation has 3 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing rosuvastatin in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Combination therapy of ezetimibe with a low-dose statin is occasionally used to avoid statin-related side effects in clinical practice among patients with atherosclerotic cardiovascular disease. This approach is equivalent to high-dose statin therapy to decrease LDL cholesterol level by >50%, allowing such patients to achieve LDL cholesterol target. However, it remains uncertain whether combination therapy with ezetimibe and low-dose statin verse high-dose statin monotherapy similarily suppress atherosclerotic plaque inflammation. This study is to compare high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid plaque inflammation in patients with acute coronary syndrome using 18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) imaging.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rosuvastatin 20 mg once a day for 6 months
Drug: high-dose rosuvastatin
ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Drug: low-dose rosuvastatin plus ezetimibe
rosuvastatin 20 mg once a day for 6 months
Drug pages: Rosuvastatin · Ezetimibe
ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Percent change in most-diseased segment (MDS)-tissue blood ratio (TBR) of the index vessel
Time frame: 6 months
Change in MDS TBR
Time frame: 6 months
Change in whole vessel TBR within the index vessel
Time frame: 6 months
Change in whole vessel TBR of the aorta
Time frame: 6 months
Change in total cholesterol
Time frame: 6 months
Change in triglyceride
Time frame: 6 months
Change in HDL-cholesterol
Time frame: 6 months
Change in LDL-cholesterol
Time frame: 6 months
Change in high sensitive C-reactive protein
Time frame: 6 months
Ran from Jun 2017 to primary completion in Jul 2019, 24 months.
Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Ezetimibe